We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Apeiron Acquires Option to License Rights to Novel Oncology Compounds from Cleveland Clinic

News   Jul 04, 2011

 
Apeiron Acquires Option to License Rights to Novel Oncology Compounds from Cleveland Clinic
 
 
 

RELATED ARTICLES

Ranitidine Recalled Due to Potential Carcinogen Contamination

News

Teva UK Ltd is recalling unexpired stock of certain batches of two types of Ranitidine medicines – used to treat conditions such as heartburn and stomach ulcers.

READ MORE

International Alliance Aims To Detect the (Almost) Undetectable

News

A new transatlantic research alliance aims to develop radical new strategies and technologies to detect cancer at its earliest stage.

READ MORE

Compound Kills Chemotherapy-resistant Cancer Cells

News

Study reports the discovery of a compound that is capable of killing chemotherapy-resistant glioblastoma-initiating cells (GICs), raising hopes of producing drugs capable of eradicating refractory tumors with low toxicity.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE